Gynecomastia risk factors

Jump to navigation Jump to search

Gynecomastia Microchapters

Home

Patient Information

Overview

Historical Perspective

Classification

Pathophysiology

Causes

Differentiating Gynecomastia from other Diseases

Epidemiology and Demographics

Risk Factors

Screening

Natural History, Complications and Prognosis

Diagnosis

Diagnostic study of choice

History and Symptoms

Physical Examination

Laboratory Findings

Electrocardiogram

Chest X Ray

CT

MRI

Ultrasound

Other Imaging Findings

Other Diagnostic Studies

Treatment

Medical Therapy

Surgery

Primary Prevention

Secondary Prevention

Cost-Effectiveness of Therapy

Future or Investigational Therapies

Case Studies

Case #1

Gynecomastia risk factors On the Web

Most recent articles

Most cited articles

Review articles

CME Programs

Powerpoint slides

Images

American Roentgen Ray Society Images of Gynecomastia risk factors

All Images
X-rays
Echo & Ultrasound
CT Images
MRI

Ongoing Trials at Clinical Trials.gov

US National Guidelines Clearinghouse

NICE Guidance

FDA on Gynecomastia risk factors

CDC on Gynecomastia risk factors

Gynecomastia risk factors in the news

Blogs on Gynecomastia risk factors

Directions to Hospitals Treating Gynecomastia

Risk calculators and risk factors for Gynecomastia risk factors

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Husnain Shaukat, M.D [2]; Omodamola Aje B.Sc, M.D. [3]

Overview

Common risk factors in the development of gynecomastia include the use of medicationscirrhosis, and hyperthyroidism. The less common risk factors include aromatase overexpression, androgen insensitivity syndrome and testosterone pathway defects.

Risk factors

Risk factors in the development of gynecomastia include:[1][2][3][4][5][6][7][8]

Common Risk Factors

Less Common Risk Factors

References

  1. Wiseman EH, Chang YH, Lombardino JG (1976). "Piroxicam, a novel anti-inflammatory agent". Arzneimittelforschung. 26 (7): 1300–3. PMID 12765.
  2. Rose LI, Underwood RH, Newmark SR, Kisch ES, Williams GH (1977). "Pathophysiology of spironolactone-induced gynecomastia". Ann Intern Med. 87 (4): 398–403. PMID 907238.
  3. Deepinder F, Braunstein GD (2012). "Drug-induced gynecomastia: an evidence-based review". Expert Opin Drug Saf. 11 (5): 779–95. doi:10.1517/14740338.2012.712109. PMID 22862307.
  4. Braunstein GD (1993). "Gynecomastia". N Engl J Med. 328 (7): 490–5. doi:10.1056/NEJM199302183280708. PMID 8421478.
  5. JACOBS EC (1948). "Gynecomastia following severe starvation". Ann Intern Med. 28 (4): 792–7. PMID 18911010.
  6. Tseng A, Horning SJ, Freiha FS, Resser KJ, Hannigan JF, Torti FM (1985). "Gynecomastia in testicular cancer patients. Prognostic and therapeutic implications". Cancer. 56 (10): 2534–8. PMID 4042075.
  7. Olivo J, Gordon GG, Rafii F, Southren AL (1975). "Estrogen metabolism in hyperthyroidism and in cirrhosis of the liver". Steroids. 26 (1): 47–56. PMID 1166483.
  8. Freeman RM, Lawton RL, Fearing MO (1968). "Gynecomastia: an endocrinologic complication of hemodialysis". Ann Intern Med. 69 (1): 67–72. PMID 5658367.

Template:WH Template:WS